<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6963560/results/search/disease/results.xml">
  <result pre="doi: 10.3390/pathogens8040176pathogens-08-00176 : Review Direct-Acting Antiviral Agents for HCV-Associated Glomerular" exact="Disease" post="and the Current Evidence FabriziFabrizio1*CeruttiRoberta1PorataGiulia1MessaPiergiorgio12https://orcid.org/0000-0002-3321-0683RidruejoEzequiel345[1], roberta.cerutti@policlinico.mi.itGiulia.porata@policlinico.mi.itPiergiorgio.messa@policlinico.mi.it[2], [3], eridruejo@gmail.com[4], [5],"/>
  <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Glomerular" exact="disease" post="is an extra-hepatic manifestation of hepatitis C virus infection"/>
  <result pre="license (http://creativecommons.org/licenses/by/4.0/). Abstract Glomerular disease is an extra-hepatic manifestation of" exact="hepatitis" post="C virus infection (HCV) and membranoproliferative glomerulonephritis is the"/>
  <result pre="Abstract Glomerular disease is an extra-hepatic manifestation of hepatitis C" exact="virus infection" post="(HCV) and membranoproliferative glomerulonephritis is the most frequent glomerular"/>
  <result pre="Glomerular disease is an extra-hepatic manifestation of hepatitis C virus" exact="infection" post="(HCV) and membranoproliferative glomerulonephritis is the most frequent glomerular"/>
  <result pre="an extra-hepatic manifestation of hepatitis C virus infection (HCV) and" exact="membranoproliferative glomerulonephritis" post="is the most frequent glomerular disease associated with HCV."/>
  <result pre="extra-hepatic manifestation of hepatitis C virus infection (HCV) and membranoproliferative" exact="glomerulonephritis" post="is the most frequent glomerular disease associated with HCV."/>
  <result pre="infection (HCV) and membranoproliferative glomerulonephritis is the most frequent glomerular" exact="disease" post="associated with HCV. It occurs commonly in patients with"/>
  <result pre="with HCV. It occurs commonly in patients with HCV-related mixed" exact="cryoglobulinemia" post="syndrome. Patients with HCV-related glomerular disease have been historically"/>
  <result pre="patients with HCV-related mixed cryoglobulinemia syndrome. Patients with HCV-related glomerular" exact="disease" post="have been historically a difficult-to-treat group. The therapeutic armamentarium"/>
  <result pre="historically a difficult-to-treat group. The therapeutic armamentarium for HCV-related glomerular" exact="disease" post="now includes antiviral regimens, selective or non-specific immunosuppressive drugs,"/>
  <result pre="includes antiviral regimens, selective or non-specific immunosuppressive drugs, immunomodulators, and" exact="symptomatic" post="agents. The treatment of HCV-associated glomerular disease is dependent"/>
  <result pre="drugs, immunomodulators, and symptomatic agents. The treatment of HCV-associated glomerular" exact="disease" post="is dependent on the clinical presentation of the patient."/>
  <result pre="have been approved for HCV even in patients with advanced" exact="chronic" post="kidney disease. According to a systematic review of the"/>
  <result pre="been approved for HCV even in patients with advanced chronic" exact="kidney disease." post="According to a systematic review of the medical literature,"/>
  <result pre="the efficacy/safety of direct-acting antiviral agents (DAAs) of HCV-induced glomerular" exact="disease" post="is limited. The frequency of sustained virological response was"/>
  <result pre="frequency of sustained virological response was 92.5% (62/67). Full or" exact="partial" post="clinical remission was demonstrated in many patients (n ="/>
  <result pre="DAAs. A few cases of new onset or relapsing glomerular" exact="disease" post="in patients with HCV successfully treated with DAAs have"/>
  <result pre="easier the management of HCV. However, patients with HCV-induced glomerular" exact="disease" post="are still a difficult-to-treat group even at the time"/>
  <result pre="group even at the time of DAAs. direct-acting antiviral agents" exact="glomerulonephritis" post="hepatitis C virus mixed cryoglobulinemia proteinuria sustained virological response"/>
  <result pre="even at the time of DAAs. direct-acting antiviral agents glomerulonephritis" exact="hepatitis" post="C virus mixed cryoglobulinemia proteinuria sustained virological response 1."/>
  <result pre="of DAAs. direct-acting antiviral agents glomerulonephritis hepatitis C virus mixed" exact="cryoglobulinemia" post="proteinuria sustained virological response 1. Introduction More than 71"/>
  <result pre="virological response 1. Introduction More than 71 million people have" exact="chronic hepatitis" post="C virus (HCV) infection worldwide. HCV is a major"/>
  <result pre="response 1. Introduction More than 71 million people have chronic" exact="hepatitis" post="C virus (HCV) infection worldwide. HCV is a major"/>
  <result pre="than 71 million people have chronic hepatitis C virus (HCV)" exact="infection" post="worldwide. HCV is a major health problem, and long"/>
  <result pre="a major health problem, and long lasting HCV results in" exact="chronic hepatitis," post="cirrhosis, and hepatocellular carcinoma. HCV plays both a hepatotropic"/>
  <result pre="and long lasting HCV results in chronic hepatitis, cirrhosis, and" exact="hepatocellular carcinoma." post="HCV plays both a hepatotropic and lymphotropic activity and"/>
  <result pre="and lymphotropic activity and is an important antigenic stimulus for" exact="clonal" post="B cell expansion. The detection of circulating cryoglobulins is"/>
  <result pre="The detection of circulating cryoglobulins is frequent in patients with" exact="chronic" post="HCV (up to 50%) but only 2–3% develop vasculitic"/>
  <result pre="50%) but only 2–3% develop vasculitic symptoms that characterize HCV-mixed" exact="cryoglobulinemia" post="syndrome. HCV infection is the main cause of mixed"/>
  <result pre="2–3% develop vasculitic symptoms that characterize HCV-mixed cryoglobulinemia syndrome. HCV" exact="infection" post="is the main cause of mixed cryoglobulinemia, a systemic"/>
  <result pre="HCV infection is the main cause of mixed cryoglobulinemia, a" exact="systemic" post="vasculitis producing various clinical manifestations which range from the"/>
  <result pre="infection is the main cause of mixed cryoglobulinemia, a systemic" exact="vasculitis" post="producing various clinical manifestations which range from the so-called"/>
  <result pre="more frequent in women than men and affects patients with" exact="cirrhosis" post="more commonly than chronic hepatitis. It appears that HCV-MCS"/>
  <result pre="than men and affects patients with cirrhosis more commonly than" exact="chronic hepatitis." post="It appears that HCV-MCS is not affected by HCV"/>
  <result pre="It appears that HCV-MCS is not affected by HCV genotype," exact="viral" post="load, or duration of HCV infection [1,2]. Mixed cryoglobulinemia"/>
  <result pre="affected by HCV genotype, viral load, or duration of HCV" exact="infection" post="[1,2]. Mixed cryoglobulinemia (MC) represents 60–75% of all cryoglobulinemia"/>
  <result pre="HCV genotype, viral load, or duration of HCV infection [1,2]." exact="Mixed" post="cryoglobulinemia (MC) represents 60–75% of all cryoglobulinemia and is"/>
  <result pre="genotype, viral load, or duration of HCV infection [1,2]. Mixed" exact="cryoglobulinemia" post="(MC) represents 60–75% of all cryoglobulinemia and is found"/>
  <result pre="HCV infection [1,2]. Mixed cryoglobulinemia (MC) represents 60–75% of all" exact="cryoglobulinemia" post="and is found in connective tissue disease and infectious"/>
  <result pre="(MC) represents 60–75% of all cryoglobulinemia and is found in" exact="connective tissue disease" post="and infectious or lymphoproliferative disorders (i.e., secondary MC) [3]."/>
  <result pre="60–75% of all cryoglobulinemia and is found in connective tissue" exact="disease" post="and infectious or lymphoproliferative disorders (i.e., secondary MC) [3]."/>
  <result pre="all cryoglobulinemia and is found in connective tissue disease and" exact="infectious" post="or lymphoproliferative disorders (i.e., secondary MC) [3]. After the"/>
  <result pre="in connective tissue disease and infectious or lymphoproliferative disorders (i.e.," exact="secondary" post="MC) [3]. After the identification of HCV, it was"/>
  <result pre="cause of 80–90% of MC. HCV is usually associated with" exact="type II" post="MC (which commonly involves an IgM k molecule showing"/>
  <result pre="activity with anti-idiopathic function), although HCV is also associated with" exact="type III" post="MC. Around 5–10% of all MCS have no clear"/>
  <result pre="Around 5–10% of all MCS have no clear etiology. Cryoglobulinemic" exact="vasculitis" post="is classified as essential or idiopathic [3]. The incidence"/>
  <result pre="as essential or idiopathic [3]. The incidence of HCV-associated glomerular" exact="disease" post="is low and this makes it difficult to conduct"/>
  <result pre="makes it difficult to conduct clinical trials to control the" exact="disease" post="[3]. Renal disease is now considered an important cause"/>
  <result pre="difficult to conduct clinical trials to control the disease [3]." exact="Renal" post="disease is now considered an important cause of morbidity"/>
  <result pre="to conduct clinical trials to control the disease [3]. Renal" exact="disease" post="is now considered an important cause of morbidity and"/>
  <result pre="considered an important cause of morbidity and mortality in MC" exact="vasculitis" post="induced by HCV [3]. Treatment of HCV has made"/>
  <result pre="IFN-free combinations of DAAs which increased dramatically the rates of" exact="viral" post="clearance [3]. The purpose of this review is to"/>
  <result pre="disease, an important extra-hepatic complication of HCV infection. 2. HCV-Associated" exact="Kidney" post="Disease: Histology Although HCV has been identified as a"/>
  <result pre="a large series [4], glomerular diseases remain the most frequent" exact="kidney disease" post="associated with HCV. The relationship between HCV and glomerular"/>
  <result pre="large series [4], glomerular diseases remain the most frequent kidney" exact="disease" post="associated with HCV. The relationship between HCV and glomerular"/>
  <result pre="disease associated with HCV. The relationship between HCV and glomerular" exact="disease" post="has been noted in both the native kidneys and"/>
  <result pre="HCV and immune complex (IC) glomerular disease, including membranoproliferative and" exact="membranous glomerulonephritis" post="[1,2]. The most common glomerular disease in HCV-positive patients"/>
  <result pre="and immune complex (IC) glomerular disease, including membranoproliferative and membranous" exact="glomerulonephritis" post="[1,2]. The most common glomerular disease in HCV-positive patients"/>
  <result pre="including membranoproliferative and membranous glomerulonephritis [1,2]. The most common glomerular" exact="disease" post="in HCV-positive patients is cryoglobulinemic membranoproliferative glomerulonephritis (MPGN). Other"/>
  <result pre="The most common glomerular disease in HCV-positive patients is cryoglobulinemic" exact="membranoproliferative glomerulonephritis" post="(MPGN). Other immune complex glomerular diseases associated with HCV"/>
  <result pre="most common glomerular disease in HCV-positive patients is cryoglobulinemic membranoproliferative" exact="glomerulonephritis" post="(MPGN). Other immune complex glomerular diseases associated with HCV"/>
  <result pre="immune complex glomerular diseases associated with HCV are non-cryoglobulinemic GN," exact="membranous nephropathy," post="IgA nephropathy, immunotactoid glomerulopathy/fibrillary glomerulonephritis (Table 1). Focal segmental"/>
  <result pre="glomerular diseases associated with HCV are non-cryoglobulinemic GN, membranous nephropathy," exact="IgA nephropathy," post="immunotactoid glomerulopathy/fibrillary glomerulonephritis (Table 1). Focal segmental glomerulosclerosis and"/>
  <result pre="HCV are non-cryoglobulinemic GN, membranous nephropathy, IgA nephropathy, immunotactoid glomerulopathy/fibrillary" exact="glomerulonephritis" post="(Table 1). Focal segmental glomerulosclerosis and mesangial proliferative glomerulonephritis"/>
  <result pre="nephropathy, IgA nephropathy, immunotactoid glomerulopathy/fibrillary glomerulonephritis (Table 1). Focal segmental" exact="glomerulosclerosis" post="and mesangial proliferative glomerulonephritis are additional forms of glomerular"/>
  <result pre="nephropathy, immunotactoid glomerulopathy/fibrillary glomerulonephritis (Table 1). Focal segmental glomerulosclerosis and" exact="mesangial proliferative glomerulonephritis" post="are additional forms of glomerular disease observed in HCV-infected"/>
  <result pre="immunotactoid glomerulopathy/fibrillary glomerulonephritis (Table 1). Focal segmental glomerulosclerosis and mesangial" exact="proliferative glomerulonephritis" post="are additional forms of glomerular disease observed in HCV-infected"/>
  <result pre="glomerulopathy/fibrillary glomerulonephritis (Table 1). Focal segmental glomerulosclerosis and mesangial proliferative" exact="glomerulonephritis" post="are additional forms of glomerular disease observed in HCV-infected"/>
  <result pre="glomerulosclerosis and mesangial proliferative glomerulonephritis are additional forms of glomerular" exact="disease" post="observed in HCV-infected patients. Polyarteritis nodosa is another uncommon"/>
  <result pre="are additional forms of glomerular disease observed in HCV-infected patients." exact="Polyarteritis nodosa" post="is another uncommon form of kidney disease associated with"/>
  <result pre="in HCV-infected patients. Polyarteritis nodosa is another uncommon form of" exact="kidney disease" post="associated with HCV. It is probably related to the"/>
  <result pre="HCV-infected patients. Polyarteritis nodosa is another uncommon form of kidney" exact="disease" post="associated with HCV. It is probably related to the"/>
  <result pre="important target of the extra-hepatic activity of HCV which causes" exact="kidney damage" post="in multiple ways. (1) HCV is a cause of"/>
  <result pre="in multiple ways. (1) HCV is a cause of tubulointerstitial" exact="nephritis" post="[2], even if this finding needs to be confirmed"/>
  <result pre="HCV-associated MCS. HCV is an important cause of MCS, a" exact="vasculitis" post="involving small to medium vessels (3). Finally, HCV supports"/>
  <result pre="(3). Finally, HCV supports the development (or the progression) of" exact="chronic" post="kidney disease in the general population, probably by vascular"/>
  <result pre="Finally, HCV supports the development (or the progression) of chronic" exact="kidney disease" post="in the general population, probably by vascular damage at"/>
  <result pre="HCV supports the development (or the progression) of chronic kidney" exact="disease" post="in the general population, probably by vascular damage at"/>
  <result pre="of chronic kidney disease in the general population, probably by" exact="vascular" post="damage at kidney level [5]. A role of chronic"/>
  <result pre="by vascular damage at kidney level [5]. A role of" exact="chronic" post="HCV infection in the pathogenesis of CKD has been"/>
  <result pre="damage at kidney level [5]. A role of chronic HCV" exact="infection" post="in the pathogenesis of CKD has been suggested by"/>
  <result pre="nature. Patients on maintenance dialysis remain at risk for HCV" exact="infection" post="due to nosocomial transmission of HCV and have a"/>
  <result pre="infection. On the other hand, a significant frequency of HCV" exact="infection" post="has been noted in patients with renal insufficiency at"/>
  <result pre="frequency of HCV infection has been noted in patients with" exact="renal insufficiency" post="at pre-dialysis stage suggesting a role of HCV in"/>
  <result pre="of large databases have addressed the relationship between HCV and" exact="chronic" post="kidney disease. According to a recent systematic review and"/>
  <result pre="large databases have addressed the relationship between HCV and chronic" exact="kidney disease." post="According to a recent systematic review and meta-analysis, aggregating"/>
  <result pre="HCV on the incidence and progression of CKD in the" exact="adult" post="general population all over the world. Endothelial dysfunction in"/>
  <result pre="CKD in the adult general population all over the world." exact="Endothelial dysfunction" post="in HCV-infected patients is in turn supported by oxidative"/>
  <result pre="patients is in turn supported by oxidative stress, pro-inflammatory cytokines," exact="peripheral" post="or hepatic insulin resistance, or non-alcoholic steatohepatitis (NASH) [5]."/>
  <result pre="10.6% (stages 3 to 5). Traditional risk factors for developing" exact="chronic" post="renal disease (diabetes mellitus, arterial hypertension, smoking, weight overload)"/>
  <result pre="(stages 3 to 5). Traditional risk factors for developing chronic" exact="renal disease" post="(diabetes mellitus, arterial hypertension, smoking, weight overload) do not"/>
  <result pre="3 to 5). Traditional risk factors for developing chronic renal" exact="disease" post="(diabetes mellitus, arterial hypertension, smoking, weight overload) do not"/>
  <result pre="Traditional risk factors for developing chronic renal disease (diabetes mellitus," exact="arterial hypertension," post="smoking, weight overload) do not explain completely the current"/>
  <result pre="weight overload) do not explain completely the current prevalence of" exact="chronic" post="kidney disease in the adult general population of industrialized"/>
  <result pre="overload) do not explain completely the current prevalence of chronic" exact="kidney disease" post="in the adult general population of industrialized world. Chronic"/>
  <result pre="do not explain completely the current prevalence of chronic kidney" exact="disease" post="in the adult general population of industrialized world. Chronic"/>
  <result pre="completely the current prevalence of chronic kidney disease in the" exact="adult" post="general population of industrialized world. Chronic infections by hepatotropic"/>
  <result pre="kidney disease in the adult general population of industrialized world." exact="Chronic" post="infections by hepatotropic viruses (hepatitis B and hepatitis C"/>
  <result pre="disease in the adult general population of industrialized world. Chronic" exact="infections" post="by hepatotropic viruses (hepatitis B and hepatitis C viruses)"/>
  <result pre="industrialized world. Chronic infections by hepatotropic viruses (hepatitis B and" exact="hepatitis" post="C viruses) or human immunodeficiency virus (HIV) are non-traditional,"/>
  <result pre="hepatotropic viruses (hepatitis B and hepatitis C viruses) or human" exact="immunodeficiency" post="virus (HIV) are non-traditional, but modifiable causes of chronic"/>
  <result pre="human immunodeficiency virus (HIV) are non-traditional, but modifiable causes of" exact="chronic" post="kidney disease [6,7]. The adverse impact of chronic HCV"/>
  <result pre="immunodeficiency virus (HIV) are non-traditional, but modifiable causes of chronic" exact="kidney disease" post="[6,7]. The adverse impact of chronic HCV on chronic"/>
  <result pre="virus (HIV) are non-traditional, but modifiable causes of chronic kidney" exact="disease" post="[6,7]. The adverse impact of chronic HCV on chronic"/>
  <result pre="causes of chronic kidney disease [6,7]. The adverse impact of" exact="chronic" post="HCV on chronic kidney disease suggests the antiviral therapy"/>
  <result pre="kidney disease [6,7]. The adverse impact of chronic HCV on" exact="chronic" post="kidney disease suggests the antiviral therapy of all HCV-infected"/>
  <result pre="disease [6,7]. The adverse impact of chronic HCV on chronic" exact="kidney disease" post="suggests the antiviral therapy of all HCV-infected patients, regardless"/>
  <result pre="[6,7]. The adverse impact of chronic HCV on chronic kidney" exact="disease" post="suggests the antiviral therapy of all HCV-infected patients, regardless"/>
  <result pre="antiviral therapy of all HCV-infected patients, regardless of their stage" exact="of liver" post="and kidney injury [3]. 4. Treatment of HCV-Related Glomerular"/>
  <result pre="all HCV-infected patients, regardless of their stage of liver and" exact="kidney injury" post="[3]. 4. Treatment of HCV-Related Glomerular Disease: Historical Perspective"/>
  <result pre="of diseases have provided the possibility to treat HCV-associated glomerular" exact="disease" post="with various approaches. (1) Antiviral therapy has been given"/>
  <result pre="therapy has been given with the idea that the underlying" exact="infection" post="promotes the synthesis of immune complexes and resultant glomerular"/>
  <result pre="the synthesis of immune complexes and resultant glomerular disease; (2)" exact="Nonspecific" post="immunosuppressive agents (corticosteroids, cyclophosphamide, azathioprine, etc.) lowering glomerular inflammation"/>
  <result pre="be effective and safe in the treatment of HCV-induced glomerular" exact="disease" post="post liver transplant due to its immunomodulatory properties [3];"/>
  <result pre="ARBs) drugs should be considered. Unlike HBV and HIV, HCV" exact="infection" post="can be completely and permanently treated by antiviral medications"/>
  <result pre="authors to report a cohort of patients with HCV-associated glomerular" exact="disease" post="who received antiviral therapy (mono-therapy with conventional IFN for"/>
  <result pre="report of Rossi et al., three patients with HCV-associated cryoglobulinemic" exact="glomerulonephritis" post="received IFN-based therapy (pegylated IFN and RBV) for 12"/>
  <result pre="Subsequent studies were performed mostly in patients with HCV-associated cryoglobulinemic" exact="vasculitis" post="(many with kidney involvement) [1,10]. All the authors observed"/>
  <result pre="arthralgias (p &amp;lt; 0.04) at baseline showed negative impact on" exact="viral" post="response [11]. The efficacy and safety of combined antiviral"/>
  <result pre="therapy was 15% (95% CI, 8–21%). A good correlation between" exact="viral" post="and clinical response (weighted K = 0.63) by a"/>
  <result pre="noted [12]. 5. Antiviral Treatment of HCV with DAAs and" exact="Renal" post="Impairment Direct-acting antiviral agents are molecules that affect the"/>
  <result pre="very effective with SVR rates around 95%, irrespective of the" exact="viral" post="characteristics of HCV. Tolerance to DAAs is very good-"/>
  <result pre="10% and early discontinuation rates less than 5% [3]. The" exact="American" post="Association for the Study of Liver Diseases (AASLD) and"/>
  <result pre="than 5% [3]. The American Association for the Study of" exact="Liver Diseases" post="(AASLD) and the Infectious Diseases Society of America (IDSA)"/>
  <result pre="5% [3]. The American Association for the Study of Liver" exact="Diseases" post="(AASLD) and the Infectious Diseases Society of America (IDSA)"/>
  <result pre="Association for the Study of Liver Diseases (AASLD) and the" exact="Infectious" post="Diseases Society of America (IDSA) have issued clinical guidelines"/>
  <result pre="for the Study of Liver Diseases (AASLD) and the Infectious" exact="Diseases" post="Society of America (IDSA) have issued clinical guidelines in"/>
  <result pre="elbasvir/grazoprevir regimen is recommended for the treatment of genotype 1" exact="infection" post="in patients with severe renal dysfunction. The C-SURFER study"/>
  <result pre="elbasvir/grazoprevir combination is effective in patients with HCV genotype 1" exact="infection" post="and CKD stage 4/5 [16]. However, elbasvir/grazoprevir shows efficacy"/>
  <result pre="pangenotypic NS5A inhibitor pibrentasvir provide a very high rate of" exact="viral" post="response in patients with HCV genotype 1, 2, 3,"/>
  <result pre="with HCV genotype 1, 2, 3, 4, 5, and 6" exact="infection" post="[17]. Finally, we suggest that serum creatinine and urinary"/>
  <result pre="patients after antiviral treatment with DAAs. New–onset or relapsing glomerular" exact="disease" post="has been noted by some authors in patients who"/>
  <result pre="on DAAs [18,19,20]. Figure 2 shows purpuric manifestations in the" exact="lower" post="limbs in a patient with HCV-related cryogobulinemic patient who"/>
  <result pre="serum. The patient suffered from frequent and spontaneous episodes of" exact="purpura" post="over the observation period (i.e., three or four times"/>
  <result pre="the observation period (i.e., three or four times a year)." exact="Purpura" post="disappeared spontaneously in most cases. 6. Antiviral Treatment of"/>
  <result pre="cases. 6. Antiviral Treatment of HCV (DAAs) for HCV-Related Glomerular" exact="Disease" post="As shown in Table 3, reports regarding DAA-based regimens"/>
  <result pre="in Table 3, reports regarding DAA-based regimens for HCV-related glomerular" exact="disease" post="are limited [21,22,23,24,25,26,27,28,29]. Collectively, the frequency of SVR was"/>
  <result pre="3, reports regarding DAA-based regimens for HCV-related glomerular disease are" exact="limited" post="[21,22,23,24,25,26,27,28,29]. Collectively, the frequency of SVR was 92% (62/67)."/>
  <result pre="the frequency of SVR was 92% (62/67). The rate of" exact="complete" post="clinical response after DAAs was 32.8% (22/67). A number"/>
  <result pre="Table 3 is incomplete. As an example, the details on" exact="kidney disease" post="(including kidney biopsy) at baseline and after antiviral therapy"/>
  <result pre="3 is incomplete. As an example, the details on kidney" exact="disease" post="(including kidney biopsy) at baseline and after antiviral therapy"/>
  <result pre="was not extensively given. The low incidence of HCV-related glomerular" exact="disease" post="clearly hampers the conduction of RCTs or observational studies"/>
  <result pre="At our knowledge, at least 11 patients with HCV-associated glomerular" exact="disease" post="experienced clinical benefit after completing therapy with DAAs [29,30,31,32,33,34]."/>
  <result pre="clinical improvement of glomerular abnormalities. However, the clinical remission was" exact="incomplete" post="or lacking in many patients (Table 3). HCV-related glomerular"/>
  <result pre="incomplete or lacking in many patients (Table 3). HCV-related glomerular" exact="disease" post="is not easily controlled by antiviral therapies, particularly in"/>
  <result pre="sclerotic injury. Also, information on DAAs efficacy in HCV-associated cryoglobulinemic" exact="vasculitis" post="is disappointing due to the inability of these drugs"/>
  <result pre="once it has been triggered. In other words, even with" exact="viral" post="eradication, the course of mixed cryoglobulinemic disease or cryoglobulinemic"/>
  <result pre="words, even with viral eradication, the course of mixed cryoglobulinemic" exact="disease" post="or cryoglobulinemic glomerulonephritis is difficult to predict. The natural"/>
  <result pre="viral eradication, the course of mixed cryoglobulinemic disease or cryoglobulinemic" exact="glomerulonephritis" post="is difficult to predict. The natural history of HCV-induced"/>
  <result pre="is difficult to predict. The natural history of HCV-induced mixed" exact="cryoglobulinemia" post="is clinically variable. Some patients have an indolent course"/>
  <result pre="of extra-renal symptoms is often associated with a flare-up of" exact="kidney disease," post="but can occur independently. No link between serum complement"/>
  <result pre="complement or rheumatoid factor levels and the course of cryoglobulinemic" exact="glomerulonephritis" post="has been noted. However, the clearance of HCV RNA"/>
  <result pre="the introduction of DAAs provided with reduced treatment duration and" exact="lower" post="prices; this will be an additional advance in the"/>
  <result pre="be an additional advance in the management of HCV-related glomerular" exact="disease" post="as these patients frequently receive multiple medications due to"/>
  <result pre="to HCV. 7. Immunosuppressive Agents for Treatment of HCV-Related Glomerular" exact="Disease" post="As mentioned above, the therapeutic armamentarium for HCV-related glomerular"/>
  <result pre="Disease As mentioned above, the therapeutic armamentarium for HCV-related glomerular" exact="disease" post="includes numerous agents in addition to antivirals. Immunosuppression has"/>
  <result pre="been employed in the past as first-line therapy in cryoglobulinemic" exact="vasculitis" post="(particularly when kidney involvement is severe) despite the possibility"/>
  <result pre="infections. Table 4 shows that the management of HCV-related glomerular" exact="disease" post="is based on the clinical manifestations of glomerular disease."/>
  <result pre="exchange. Current practice is to treat with immunosuppressants until the" exact="acute" post="phase of disease is overcome. After that, treatment with"/>
  <result pre="is to treat with immunosuppressants until the acute phase of" exact="disease" post="is overcome. After that, treatment with DAAs is suggested."/>
  <result pre="clinician. Patients with mild or moderate forms of HCV-induced glomerular" exact="disease" post="(stable kidney function and/or non-nephrotic proteinuria) should be treated"/>
  <result pre="proteinuria) should be treated with DAAs. Patients with HCV-induced glomerular" exact="disease" post="who are resistant or intolerant to DAA therapies should"/>
  <result pre="where clinically requested. 8. Rituximab for Treatment of HCV-Related Glomerular" exact="Disease" post="RTX is currently the first-line immunosuppressive agent for HCV-related"/>
  <result pre="Disease RTX is currently the first-line immunosuppressive agent for HCV-related" exact="glomerulonephritis" post="[3]. RTX is a monoclonal antibody directed at the"/>
  <result pre="cyclophosphamide, and plasma exchange) for the management of HCV-associated cryoglobulinemic" exact="vasculitis" post="in individuals for whom prior IFN therapy failed to"/>
  <result pre="in individuals for whom prior IFN therapy failed to give" exact="disease" post="remission, or in patients who were not eligible for"/>
  <result pre="patients suffered from kidney involvement. Over 400 patients with mixed" exact="cryoglobulinemia" post="have been treated with RTX according to a recent"/>
  <result pre="been recently published- 31 patients (27 infected with HCV) with" exact="symptomatic" post="MC (MC type 2 in 29 patients and MC"/>
  <result pre="31 patients (27 infected with HCV) with symptomatic MC (MC" exact="type 2" post="in 29 patients and MC type 3 in two"/>
  <result pre="symptomatic MC (MC type 2 in 29 patients and MC" exact="type 3" post="in two patients) received RTX [38]. There were 16"/>
  <result pre="two patients) received RTX [38]. There were 16 patients with" exact="diffuse" post="MPGN, 26 patients with peripheral neuropathy, and seven with"/>
  <result pre="There were 16 patients with diffuse MPGN, 26 patients with" exact="peripheral neuropathy," post="and seven with severe skin ulcers. RTX was given"/>
  <result pre="additional immunosuppressive medications or antiviral agents were administered. We observed" exact="complete" post="disappearance of pre-treatment manifestations in all patients with purpuric"/>
  <result pre="purpuric changes and non-healing vasculitic ulcers, and in 80% of" exact="peripheral" post="neuropathies. Cryoglobulinemic nephropathy consistently improved during the observation period,"/>
  <result pre="non-healing vasculitic ulcers, and in 80% of peripheral neuropathies. Cryoglobulinemic" exact="nephropathy" post="consistently improved during the observation period, starting from the"/>
  <result pre="have reported that among patients (n = 23) having non-viral" exact="cryoglobulinemia" post="vasculitis on RTX, side effects occurred in almost half"/>
  <result pre="reported that among patients (n = 23) having non-viral cryoglobulinemia" exact="vasculitis" post="on RTX, side effects occurred in almost half of"/>
  <result pre="the patients (n = 11), including severe infections. Episodes of" exact="infection" post="had been observed mainly in a subgroup of patients"/>
  <result pre="in a subgroup of patients (age &amp;gt; 70 years, essential" exact="type II" post="MC, GFR &amp;lt; 60 mL/min/1.73 m2, and simultaneous high"/>
  <result pre="following RTX administration [40]. One single dose of RTX for" exact="gastric lymphoma" post="resulted in the occurrence of cholestatic hepatitis in a"/>
  <result pre="RTX administration [40]. One single dose of RTX for gastric" exact="lymphoma" post="resulted in the occurrence of cholestatic hepatitis in a"/>
  <result pre="RTX for gastric lymphoma resulted in the occurrence of cholestatic" exact="hepatitis" post="in a renal transplant (RT) recipient with chronic HCV."/>
  <result pre="of cholestatic hepatitis in a renal transplant (RT) recipient with" exact="chronic" post="HCV. An enormous increase of HCV RNA levels after"/>
  <result pre="RTX administration was noted and the patient died due to" exact="bacterial" post="pneumonia [41]. 9. Non-Selective Immunosuppression for HCV-Related Glomerular Disease"/>
  <result pre="administration was noted and the patient died due to bacterial" exact="pneumonia" post="[41]. 9. Non-Selective Immunosuppression for HCV-Related Glomerular Disease Plasma"/>
  <result pre="to bacterial pneumonia [41]. 9. Non-Selective Immunosuppression for HCV-Related Glomerular" exact="Disease" post="Plasma exchange has been considered for many years the"/>
  <result pre="to alleviate inflammation at glomerular level. However, steroids support progressive" exact="liver disease" post="and replication of HCV [3]. Cyclophosphamide has been selected"/>
  <result pre="alleviate inflammation at glomerular level. However, steroids support progressive liver" exact="disease" post="and replication of HCV [3]. Cyclophosphamide has been selected"/>
  <result pre="of HCV [3]. Cyclophosphamide has been selected to improve glomerular" exact="disease" post="by lowering stimulation of B lymphocytes and cryoglobulin synthesis."/>
  <result pre="cell-mediated immune responses. Evidence on mycophenolate mofetil for HCV-associated glomerular" exact="disease" post="is extremely limited [43]. 10. Conclusions The present review"/>
  <result pre="Evidence on mycophenolate mofetil for HCV-associated glomerular disease is extremely" exact="limited" post="[43]. 10. Conclusions The present review shows that antiviral"/>
  <result pre="glomerular disease. Tolerance was satisfactory with no serious adverse events." exact="Viral" post="response is accompanied with some clinical benefit and immunosuppressive"/>
  <result pre="therapies are required in many cases. Patients with HCV-induced glomerular" exact="disease" post="are still a difficult-to-treat group even at the time"/>
  <result pre="will reduce the need of immunosuppressive drugs for HCV-related glomerular" exact="disease" post="is a topic of active research. Funding This research"/>
  <result pre="a topic of active research. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
  <result pre="AEs Adverse events ARBs Angiotensin-receptor blockers CI Confidence Intervals CKD" exact="Chronic" post="kidney disease DAAs Direct-acting antiviral agents DCV Daclatasvir 3D"/>
  <result pre="Adverse events ARBs Angiotensin-receptor blockers CI Confidence Intervals CKD Chronic" exact="kidney disease" post="DAAs Direct-acting antiviral agents DCV Daclatasvir 3D Ritonavir-boosted paritaprevir/ombitasvir/dasabuvir"/>
  <result pre="events ARBs Angiotensin-receptor blockers CI Confidence Intervals CKD Chronic kidney" exact="disease" post="DAAs Direct-acting antiviral agents DCV Daclatasvir 3D Ritonavir-boosted paritaprevir/ombitasvir/dasabuvir"/>
  <result pre="paritaprevir/ombitasvir/dasabuvir EBR Elbasvir eGFR Estimated glomerular filtration rate ESRD End-stage" exact="renal disease" post="FDV Faldaprevir GRZ Grazoprevir GN Glomerulonephritis HBV Hepatitis B"/>
  <result pre="EBR Elbasvir eGFR Estimated glomerular filtration rate ESRD End-stage renal" exact="disease" post="FDV Faldaprevir GRZ Grazoprevir GN Glomerulonephritis HBV Hepatitis B"/>
  <result pre="rate ESRD End-stage renal disease FDV Faldaprevir GRZ Grazoprevir GN" exact="Glomerulonephritis" post="HBV Hepatitis B virus HCV Hepatitis C virus HIV"/>
  <result pre="End-stage renal disease FDV Faldaprevir GRZ Grazoprevir GN Glomerulonephritis HBV" exact="Hepatitis" post="B virus HCV Hepatitis C virus HIV Human immunodeficiency"/>
  <result pre="Faldaprevir GRZ Grazoprevir GN Glomerulonephritis HBV Hepatitis B virus HCV" exact="Hepatitis" post="C virus HIV Human immunodeficiency virus HD Haemodialysis MCS"/>
  <result pre="HBV Hepatitis B virus HCV Hepatitis C virus HIV Human" exact="immunodeficiency" post="virus HD Haemodialysis MCS Mixed cryoglobulinemia syndrome MPGN Membranoproliferative"/>
  <result pre="Hepatitis C virus HIV Human immunodeficiency virus HD Haemodialysis MCS" exact="Mixed" post="cryoglobulinemia syndrome MPGN Membranoproliferative glomerulonephritis IFN Interferon LDV Ledipasvir"/>
  <result pre="C virus HIV Human immunodeficiency virus HD Haemodialysis MCS Mixed" exact="cryoglobulinemia" post="syndrome MPGN Membranoproliferative glomerulonephritis IFN Interferon LDV Ledipasvir pegIFN"/>
  <result pre="virus HIV Human immunodeficiency virus HD Haemodialysis MCS Mixed cryoglobulinemia" exact="syndrome" post="MPGN Membranoproliferative glomerulonephritis IFN Interferon LDV Ledipasvir pegIFN Pegylated"/>
  <result pre="immunodeficiency virus HD Haemodialysis MCS Mixed cryoglobulinemia syndrome MPGN Membranoproliferative" exact="glomerulonephritis" post="IFN Interferon LDV Ledipasvir pegIFN Pegylated interferon RBV Ribavirin"/>
  <result pre="Ledipasvir pegIFN Pegylated interferon RBV Ribavirin RF Rheumatoid factor RT" exact="Renal" post="transplant RTX Rituximab SIM Simeprevir SOF Sofosbuvir SVR Sustained"/>
  <result pre="SOF Sofosbuvir SVR Sustained virological response References References 1.FabriziF.PlaisierE.SaadounD.MartinP.MessaP.CacoubP.Hepatitis C" exact="virus infection," post="mixed cryoglobulinemia, and kidney diseaseAm. J. Kidney Dis.20136162363710.1053/j.ajkd.2012.08.04023102733 2.RutledgeS.ChungT.SiseM.Treatment"/>
  <result pre="1.FabriziF.PlaisierE.SaadounD.MartinP.MessaP.CacoubP.Hepatitis C virus infection, mixed cryoglobulinemia, and kidney diseaseAm. J." exact="Kidney" post="Dis.20136162363710.1053/j.ajkd.2012.08.04023102733 2.RutledgeS.ChungT.SiseM.Treatment of hepatitis C virus infection in patients"/>
  <result pre="mixed cryoglobulinemia, and kidney diseaseAm. J. Kidney Dis.20136162363710.1053/j.ajkd.2012.08.04023102733 2.RutledgeS.ChungT.SiseM.Treatment of" exact="hepatitis" post="C virus infection in patients with mixed cryoglobulinemic syndrome"/>
  <result pre="and kidney diseaseAm. J. Kidney Dis.20136162363710.1053/j.ajkd.2012.08.04023102733 2.RutledgeS.ChungT.SiseM.Treatment of hepatitis C" exact="virus infection" post="in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritisHemodial."/>
  <result pre="kidney diseaseAm. J. Kidney Dis.20136162363710.1053/j.ajkd.2012.08.04023102733 2.RutledgeS.ChungT.SiseM.Treatment of hepatitis C virus" exact="infection" post="in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritisHemodial."/>
  <result pre="of hepatitis C virus infection in patients with mixed cryoglobulinemic" exact="syndrome" post="and cryoglobulinemic glomerulonephritisHemodial. Int.201822S81S9610.1111/hdi.1264929694729 3.collab: Kidney Disease Improving Global"/>
  <result pre="patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritisHemodial. Int.201822S81S9610.1111/hdi.1264929694729 3.collab:" exact="Kidney" post="Disease Improving Global Outcomes (KDIGO) Hepatitis C Work GroupKDIGO"/>
  <result pre="with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritisHemodial. Int.201822S81S9610.1111/hdi.1264929694729 3.collab: Kidney" exact="Disease" post="Improving Global Outcomes (KDIGO) Hepatitis C Work GroupKDIGO 2018"/>
  <result pre="cryoglobulinemic glomerulonephritisHemodial. Int.201822S81S9610.1111/hdi.1264929694729 3.collab: Kidney Disease Improving Global Outcomes (KDIGO)" exact="Hepatitis" post="C Work GroupKDIGO 2018 Clinical Pratice Guideline for the"/>
  <result pre="Pratice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of" exact="Hepatitis" post="C in Chronic Kidney DiseaseKidney Int. Suppl.201889116510.1016/j.kisu.2018.06.00130675443 4.KasunoK.OnoT.MatsumoriA.NogakiF.KusanoH.WatanabeH.YodoiJ.MusoE.Hepatitis C"/>
  <result pre="the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in" exact="Chronic" post="Kidney DiseaseKidney Int. Suppl.201889116510.1016/j.kisu.2018.06.00130675443 4.KasunoK.OnoT.MatsumoriA.NogakiF.KusanoH.WatanabeH.YodoiJ.MusoE.Hepatitis C virus-associated tubulo-interstitial injuryAm."/>
  <result pre="Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic" exact="Kidney" post="DiseaseKidney Int. Suppl.201889116510.1016/j.kisu.2018.06.00130675443 4.KasunoK.OnoT.MatsumoriA.NogakiF.KusanoH.WatanabeH.YodoiJ.MusoE.Hepatitis C virus-associated tubulo-interstitial injuryAm. J."/>
  <result pre="Kidney DiseaseKidney Int. Suppl.201889116510.1016/j.kisu.2018.06.00130675443 4.KasunoK.OnoT.MatsumoriA.NogakiF.KusanoH.WatanabeH.YodoiJ.MusoE.Hepatitis C virus-associated tubulo-interstitial injuryAm. J." exact="Kidney" post="Dis.20034176777510.1016/S0272-6386(03)00024-612666063 5.FabriziF.DonatoF.MessaP.Association between hepatitis C virus and chronic kidney"/>
  <result pre="4.KasunoK.OnoT.MatsumoriA.NogakiF.KusanoH.WatanabeH.YodoiJ.MusoE.Hepatitis C virus-associated tubulo-interstitial injuryAm. J. Kidney Dis.20034176777510.1016/S0272-6386(03)00024-612666063 5.FabriziF.DonatoF.MessaP.Association between" exact="hepatitis" post="C virus and chronic kidney disease: A systematic review"/>
  <result pre="injuryAm. J. Kidney Dis.20034176777510.1016/S0272-6386(03)00024-612666063 5.FabriziF.DonatoF.MessaP.Association between hepatitis C virus and" exact="chronic" post="kidney disease: A systematic review and meta-analysisAnn. Hepatol.20181736439110.5604/01.3001.0011.738229735788 6.FabriziF.DonatoF.MessaP.Association"/>
  <result pre="kidney disease: A systematic review and meta-analysisAnn. Hepatol.20181736439110.5604/01.3001.0011.738229735788 6.FabriziF.DonatoF.MessaP.Association between" exact="hepatitis" post="B virus and chronic kidney disease: A systematic review"/>
  <result pre="review and meta-analysisAnn. Hepatol.20181736439110.5604/01.3001.0011.738229735788 6.FabriziF.DonatoF.MessaP.Association between hepatitis B virus and" exact="chronic" post="kidney disease: A systematic review and meta-analysisAnn. Hepatol.201716214710.5604/16652681.1226813 7.RossiC.RaboudJ.WalmsleyS.CooperC.AntoniouT.BurchellA.N.HullM.ChiaJ.HoggR.S.MoodieE.E.et"/>
  <result pre="meta-analysisAnn. Hepatol.201716214710.5604/16652681.1226813 7.RossiC.RaboudJ.WalmsleyS.CooperC.AntoniouT.BurchellA.N.HullM.ChiaJ.HoggR.S.MoodieE.E.et al.The Canadian Observational Cohort (CANOC) Collaboration. The" exact="Hepatitis" post="C co-infection is associated with an increased risk of"/>
  <result pre="C co-infection is associated with an increased risk of incident" exact="chronic" post="disease in HIV-infected patients initiating combination antiretroviral therapyBMC Infect."/>
  <result pre="co-infection is associated with an increased risk of incident chronic" exact="disease" post="in HIV-infected patients initiating combination antiretroviral therapyBMC Infect. Dis.20171724610.1186/s12879-017-2350-828376824"/>
  <result pre="HIV-infected patients initiating combination antiretroviral therapyBMC Infect. Dis.20171724610.1186/s12879-017-2350-828376824 8.JohnsonR.J.GretchD.R.YamabeH.HartJ.BacchiC.E.HartwellP.CouserW.G.CoreyL.WenerM.H.AlpersC.E.et al.Membranoproliferative" exact="glomerulonephritis" post="associated with hepatitis C virus infectionN. Engl. J. Med.199332846547010.1056/NEJM1993021832807037678440"/>
  <result pre="combination antiretroviral therapyBMC Infect. Dis.20171724610.1186/s12879-017-2350-828376824 8.JohnsonR.J.GretchD.R.YamabeH.HartJ.BacchiC.E.HartwellP.CouserW.G.CoreyL.WenerM.H.AlpersC.E.et al.Membranoproliferative glomerulonephritis associated with" exact="hepatitis" post="C virus infectionN. Engl. J. Med.199332846547010.1056/NEJM1993021832807037678440 9.RossiP.BertaniT.BaioP.CaldaraR.LuliriP.TengattiniF.BellavitaP.MazzuccoG.MisianiR.Hepatitis C virus-related"/>
  <result pre="remission after antiviral therapyKidney Int.2003632236224110.1046/j.1523-1755.2003.00022.x12753313 10.AlricL.PlaisierE.ThébaultS.PéronJ.M.RostaingL.PourratJ.RoncoP.PietteJ.C.CacoubP.Influence of antiviral therapy in" exact="hepatitis" post="C-associated cryoglobulinemic membranoproliferative glomerulonephritisAm. J. Kidney Dis.20044361762310.1053/j.ajkd.2003.11.02015042538 11.FabriziF.DixitV.MessaP.Interferon mono-therapy"/>
  <result pre="of antiviral therapy in hepatitis C-associated cryoglobulinemic membranoproliferative glomerulonephritisAm. J." exact="Kidney" post="Dis.20044361762310.1053/j.ajkd.2003.11.02015042538 11.FabriziF.DixitV.MessaP.Interferon mono-therapy for symptomatic HCV associated mixed cryoglobulinemia:"/>
  <result pre="C-associated cryoglobulinemic membranoproliferative glomerulonephritisAm. J. Kidney Dis.20044361762310.1053/j.ajkd.2003.11.02015042538 11.FabriziF.DixitV.MessaP.Interferon mono-therapy for" exact="symptomatic" post="HCV associated mixed cryoglobulinemia: Meta-analysis of clinical studiesActa Gastroenterol."/>
  <result pre="cryoglobulinemia: Meta-analysis of clinical studiesActa Gastroenterol. Belg.20137636337124592538 12.FabriziF.DixitV.MessaP.Antiviral therapy of" exact="symptomatic" post="HCV associated mixed cryoglobulinemia: Meta-analysis of clinical studiesJ. Med."/>
  <result pre="in the era of direct acting antiviral agentsFront. Med.201962010.3389/fmed.2019.0002030800660 14.collab:" exact="American" post="Association for the Study of Liver Diseases (AASLD) and"/>
  <result pre="antiviral agentsFront. Med.201962010.3389/fmed.2019.0002030800660 14.collab: American Association for the Study of" exact="Liver Diseases" post="(AASLD) and Infectious Disease Society of America (IDSA)HCV Guidance:"/>
  <result pre="agentsFront. Med.201962010.3389/fmed.2019.0002030800660 14.collab: American Association for the Study of Liver" exact="Diseases" post="(AASLD) and Infectious Disease Society of America (IDSA)HCV Guidance:"/>
  <result pre="American Association for the Study of Liver Diseases (AASLD) and" exact="Infectious" post="Disease Society of America (IDSA)HCV Guidance: Recommendations for Testing,"/>
  <result pre="Association for the Study of Liver Diseases (AASLD) and Infectious" exact="Disease" post="Society of America (IDSA)HCV Guidance: Recommendations for Testing, Managing,"/>
  <result pre="of America (IDSA)HCV Guidance: Recommendations for Testing, Managing, and Treating" exact="Hepatitis" post="CAvailable online: http://hcv.guidelines.org(accessed on 21 September 2017) 15.SaxenaV.KoraishyF.M.SiseM.E.LimJ.K.SchmidtM.ChungR.T.LiapakisA.NelsonD.R.FriedM.W.TerraultN.A.et al.Safety"/>
  <result pre="September 2017) 15.SaxenaV.KoraishyF.M.SiseM.E.LimJ.K.SchmidtM.ChungR.T.LiapakisA.NelsonD.R.FriedM.W.TerraultN.A.et al.Safety and efficacy of sofosbuvir-containing regimens in" exact="hepatitis" post="C-infected patients with impaired renal functionLiver Int.20163680781610.1111/liv.1310226923436 16.RothD.NelsonD.R.BruchfeldA.LiapakisA.SilvaM.MonsourH.Jr.MartinP.PolS.LondoñoM.C.HassaneinT.et al.Grazoprevir"/>
  <result pre="al.Grazoprevir plus elbasvir in treatment naïve and treatment-experienced patients with" exact="hepatitis" post="C virus genotype 1 infection and stage 4–5 chronic"/>
  <result pre="naïve and treatment-experienced patients with hepatitis C virus genotype 1" exact="infection" post="and stage 4–5 chronic kidney disease (the C-SURFER study)Lancet20153861537154510.1016/S0140-6736(15)00349-926456905"/>
  <result pre="with hepatitis C virus genotype 1 infection and stage 4–5" exact="chronic" post="kidney disease (the C-SURFER study)Lancet20153861537154510.1016/S0140-6736(15)00349-926456905 17.GaneE.LawitzE.PugatchD.PapatheodoridisG.BräuN.BrownA.PolS.LeroyV.PersicoM.MorenoC.et al.Glecaprevir and pibrentasvir"/>
  <result pre="hepatitis C virus genotype 1 infection and stage 4–5 chronic" exact="kidney disease" post="(the C-SURFER study)Lancet20153861537154510.1016/S0140-6736(15)00349-926456905 17.GaneE.LawitzE.PugatchD.PapatheodoridisG.BräuN.BrownA.PolS.LeroyV.PersicoM.MorenoC.et al.Glecaprevir and pibrentasvir in patients"/>
  <result pre="C virus genotype 1 infection and stage 4–5 chronic kidney" exact="disease" post="(the C-SURFER study)Lancet20153861537154510.1016/S0140-6736(15)00349-926456905 17.GaneE.LawitzE.PugatchD.PapatheodoridisG.BräuN.BrownA.PolS.LeroyV.PersicoM.MorenoC.et al.Glecaprevir and pibrentasvir in patients"/>
  <result pre="severe renal impairmentN. Engl. J. Med.20173771448145510.1056/NEJMoa170405329020583 18.SiseM.E.WisockyJ.RosalesI.A.ChuteD.HolmesJ.A.CorapiK.M.BabittJ.L.TangrenJ.S.HashemiN.LundquistA.L.et al.Lupus-like immune complex-mediated" exact="glomerulonephritis" post="in patients with hepatitis C virus infection treated with"/>
  <result pre="J. Med.20173771448145510.1056/NEJMoa170405329020583 18.SiseM.E.WisockyJ.RosalesI.A.ChuteD.HolmesJ.A.CorapiK.M.BabittJ.L.TangrenJ.S.HashemiN.LundquistA.L.et al.Lupus-like immune complex-mediated glomerulonephritis in patients with" exact="hepatitis" post="C virus infection treated with oral, interferon-free, direct-acting antiviral"/>
  <result pre="18.SiseM.E.WisockyJ.RosalesI.A.ChuteD.HolmesJ.A.CorapiK.M.BabittJ.L.TangrenJ.S.HashemiN.LundquistA.L.et al.Lupus-like immune complex-mediated glomerulonephritis in patients with hepatitis C" exact="virus infection" post="treated with oral, interferon-free, direct-acting antiviral therapyKidney Int. Rep.2016113514310.1016/j.ekir.2016.06.00627990496"/>
  <result pre="al.Lupus-like immune complex-mediated glomerulonephritis in patients with hepatitis C virus" exact="infection" post="treated with oral, interferon-free, direct-acting antiviral therapyKidney Int. Rep.2016113514310.1016/j.ekir.2016.06.00627990496"/>
  <result pre="treated with oral, interferon-free, direct-acting antiviral therapyKidney Int. Rep.2016113514310.1016/j.ekir.2016.06.00627990496 19.GhosnM.PalmerM.NajemC.HaddadD.MerkelP.HoganJ.New-onset" exact="hepatitis" post="C virus-associated glomerulonephritis following sustained virologic response with direct"/>
  <result pre="interferon-free, direct-acting antiviral therapyKidney Int. Rep.2016113514310.1016/j.ekir.2016.06.00627990496 19.GhosnM.PalmerM.NajemC.HaddadD.MerkelP.HoganJ.New-onset hepatitis C virus-associated" exact="glomerulonephritis" post="following sustained virologic response with direct acting antiviral therapyClin."/>
  <result pre="virologic response with direct acting antiviral therapyClin. Nephrol.20178726126610.5414/CN10901928332476 20.BarbieriD.García-PrietoA.TorresE.VerdeE.GoicoecheaM.LuñoJ.Mixed cryoglobulinaemia" exact="vasculitis" post="after sustained hepatitis C virological response with direct-acting antiviralsClin."/>
  <result pre="direct acting antiviral therapyClin. Nephrol.20178726126610.5414/CN10901928332476 20.BarbieriD.García-PrietoA.TorresE.VerdeE.GoicoecheaM.LuñoJ.Mixed cryoglobulinaemia vasculitis after sustained" exact="hepatitis" post="C virological response with direct-acting antiviralsClin. Kidney J.20181236236410.1093/ckj/sfy05531198535 21.GragnaniL.VisentiniM.FognaniE.UrraroT.De"/>
  <result pre="vasculitis after sustained hepatitis C virological response with direct-acting antiviralsClin." exact="Kidney" post="J.20181236236410.1093/ckj/sfy05531198535 21.GragnaniL.VisentiniM.FognaniE.UrraroT.De SantisA.PetracciaL.PerezM.CeccottiG.ColantuonoS.MitrevskiM.et al.Prospective study of guideline-tailored therapy with"/>
  <result pre="SantisA.PetracciaL.PerezM.CeccottiG.ColantuonoS.MitrevskiM.et al.Prospective study of guideline-tailored therapy with direct-acting antivirals for" exact="hepatitis" post="C virus-associated mixed cryoglobulinemiaHepatology2016641473148210.1002/hep.2875327483451 22.SiseM.E.BloomA.K.WisockyJ.LinM.V.GustafsonJ.L.LundquistA.L.SteeleD.ThiimM.WilliamsW.W.HashemiN.et al.Treatment of hepatitis C"/>
  <result pre="antivirals for hepatitis C virus-associated mixed cryoglobulinemiaHepatology2016641473148210.1002/hep.2875327483451 22.SiseM.E.BloomA.K.WisockyJ.LinM.V.GustafsonJ.L.LundquistA.L.SteeleD.ThiimM.WilliamsW.W.HashemiN.et al.Treatment of" exact="hepatitis" post="C virus-associated mixed cryoglobulinemia with sofosbuvir-based direct-acting antiviral agentsHepatology20166340841710.1002/hep.2829726474537"/>
  <result pre="virus-associated mixed cryoglobulinemiaHepatology2016641473148210.1002/hep.2875327483451 22.SiseM.E.BloomA.K.WisockyJ.LinM.V.GustafsonJ.L.LundquistA.L.SteeleD.ThiimM.WilliamsW.W.HashemiN.et al.Treatment of hepatitis C virus-associated mixed" exact="cryoglobulinemia" post="with sofosbuvir-based direct-acting antiviral agentsHepatology20166340841710.1002/hep.2829726474537 23.SaadounD.ThibaultV.AhmedS.N.S.AlricL.MalletM.GuillaudC.IzzedineH.PlaisierA.FontaineH.CostopoulosM.et al.Sofosbuvir plus ribavirin"/>
  <result pre="with sofosbuvir-based direct-acting antiviral agentsHepatology20166340841710.1002/hep.2829726474537 23.SaadounD.ThibaultV.AhmedS.N.S.AlricL.MalletM.GuillaudC.IzzedineH.PlaisierA.FontaineH.CostopoulosM.et al.Sofosbuvir plus ribavirin for" exact="hepatitis" post="C-associated cryoglobulinaemia vasculitis: Vascuvaldic studyAnn. Rheum. Dis.2016751777178210.1136/annrheumdis-2015-20833926567178 24.SollimaS.MilazzoL.PeriA.M.TorreA.AntinoriS.GalliM.Persistent mixed"/>
  <result pre="hepatitis C-associated cryoglobulinaemia vasculitis: Vascuvaldic studyAnn. Rheum. Dis.2016751777178210.1136/annrheumdis-2015-20833926567178 24.SollimaS.MilazzoL.PeriA.M.TorreA.AntinoriS.GalliM.Persistent mixed" exact="cryoglobulinemia" post="vasculitis despite hepatitis C virus eradication after interferon-free antiviral"/>
  <result pre="C-associated cryoglobulinaemia vasculitis: Vascuvaldic studyAnn. Rheum. Dis.2016751777178210.1136/annrheumdis-2015-20833926567178 24.SollimaS.MilazzoL.PeriA.M.TorreA.AntinoriS.GalliM.Persistent mixed cryoglobulinemia" exact="vasculitis" post="despite hepatitis C virus eradication after interferon-free antiviral therapyRheumatology2016552084208510.1093/rheumatology/kew26827338085"/>
  <result pre="vasculitis: Vascuvaldic studyAnn. Rheum. Dis.2016751777178210.1136/annrheumdis-2015-20833926567178 24.SollimaS.MilazzoL.PeriA.M.TorreA.AntinoriS.GalliM.Persistent mixed cryoglobulinemia vasculitis despite" exact="hepatitis" post="C virus eradication after interferon-free antiviral therapyRheumatology2016552084208510.1093/rheumatology/kew26827338085 25.EmeryJ.S.KuczynskiM.LaD.AlmarzooqiS.KowgierM.ShahH.WongD.JanssenH.L.FeldJ.J.Efficacy and"/>
  <result pre="and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated" exact="cryoglobulinemia" post="vasculitisGastroenterology2017153495210.1053/j.gastro.2017.03.00628288791 27.BonacciM.LensS.MariñoZ.LondoñoM.C.Rodriguez-TajesS.Sánchez-TapiasJ.M.Ramos-CasalsM.Hernández-RodríguezJ.FornsX.Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis"/>
  <result pre="HCV-associated cryoglobulinemia vasculitisGastroenterology2017153495210.1053/j.gastro.2017.03.00628288791 27.BonacciM.LensS.MariñoZ.LondoñoM.C.Rodriguez-TajesS.Sánchez-TapiasJ.M.Ramos-CasalsM.Hernández-RodríguezJ.FornsX.Long-term outcomes of patients with HCV-associated cryoglobulinemic" exact="vasculitis" post="after virologic cureGastroenterology201815531131510.1053/j.gastro.2018.04.02429705529 28.FabriziF.AghemoA.LamperticoP.FraquelliM.CresseriD.MoroniG.PasseriniP.DonatoF.M.MessaP.Immunosuppressive and antiviral treatment of hepatitis"/>
  <result pre="cryoglobulinemic vasculitis after virologic cureGastroenterology201815531131510.1053/j.gastro.2018.04.02429705529 28.FabriziF.AghemoA.LamperticoP.FraquelliM.CresseriD.MoroniG.PasseriniP.DonatoF.M.MessaP.Immunosuppressive and antiviral treatment of" exact="hepatitis" post="C virus-associated glomerular disease: A long-term follow-upInt. J. Artif."/>
  <result pre="long-term follow-upInt. J. Artif. Organs20184130631810.1177/039139881876235829595085 29.ObriscaB.JuribitaR.SorohanB.IliescuL.BastonC.BobeicăR.AndronesiA.LecaN.IsmailG.Clinical outcomes of HCV-associated cryoglobulinemic" exact="glomerulonephritis" post="following treatment with direct acting antiviral agents: A case-based"/>
  <result pre="agents: A case-based reviewClin. Rheumatol.201910.1007/s10067-019-04625-y 30.FabriziF.PaolucciA.AntonelliB.CeruttiR.DonatoF.M.LamperticoP.MessaP.Hepatitis C virus induced glomerular" exact="disease" post="and posterior reversible encephalopathy syndrome after liver transplant: Case"/>
  <result pre="case-based reviewClin. Rheumatol.201910.1007/s10067-019-04625-y 30.FabriziF.PaolucciA.AntonelliB.CeruttiR.DonatoF.M.LamperticoP.MessaP.Hepatitis C virus induced glomerular disease and" exact="posterior" post="reversible encephalopathy syndrome after liver transplant: Case report and"/>
  <result pre="Rheumatol.201910.1007/s10067-019-04625-y 30.FabriziF.PaolucciA.AntonelliB.CeruttiR.DonatoF.M.LamperticoP.MessaP.Hepatitis C virus induced glomerular disease and posterior reversible" exact="encephalopathy" post="syndrome after liver transplant: Case report and literature reviewSaudi"/>
  <result pre="30.FabriziF.PaolucciA.AntonelliB.CeruttiR.DonatoF.M.LamperticoP.MessaP.Hepatitis C virus induced glomerular disease and posterior reversible encephalopathy" exact="syndrome" post="after liver transplant: Case report and literature reviewSaudi J."/>
  <result pre="syndrome after liver transplant: Case report and literature reviewSaudi J." exact="Kidney" post="Dis. Transpl.20193023924910.4103/1319-2442.25291830804289 31.Zarębska-MichalukD.StępieńP.M.PaluchK.PabjanP.Retreatment of symptomatic HCV genotype 3 associated"/>
  <result pre="report and literature reviewSaudi J. Kidney Dis. Transpl.20193023924910.4103/1319-2442.25291830804289 31.Zarębska-MichalukD.StępieńP.M.PaluchK.PabjanP.Retreatment of" exact="symptomatic" post="HCV genotype 3 associated mixed cryoglobulinemia with sofosbuvir plus"/>
  <result pre="Dis. Transpl.20193023924910.4103/1319-2442.25291830804289 31.Zarębska-MichalukD.StępieńP.M.PaluchK.PabjanP.Retreatment of symptomatic HCV genotype 3 associated mixed" exact="cryoglobulinemia" post="with sofosbuvir plus ribavirin: A case reportClin. Exp. Hepatol.2018410010329904727"/>
  <result pre="Exp. Hepatol.2018410010329904727 32.ElmowafyA.Y.El MaghrabiH.M.ZahabM.A.ElwasifS.M.BakrM.A.Sofosbuvir and daclatasvir in treatment of HCV-related" exact="membranoproliferative glomerulonephritis" post="with cryoglobulinemia in a patient with HCV genotype 4Iran"/>
  <result pre="Hepatol.2018410010329904727 32.ElmowafyA.Y.El MaghrabiH.M.ZahabM.A.ElwasifS.M.BakrM.A.Sofosbuvir and daclatasvir in treatment of HCV-related membranoproliferative" exact="glomerulonephritis" post="with cryoglobulinemia in a patient with HCV genotype 4Iran"/>
  <result pre="MaghrabiH.M.ZahabM.A.ElwasifS.M.BakrM.A.Sofosbuvir and daclatasvir in treatment of HCV-related membranoproliferative glomerulonephritis with" exact="cryoglobulinemia" post="in a patient with HCV genotype 4Iran J. Kidney"/>
  <result pre="with cryoglobulinemia in a patient with HCV genotype 4Iran J." exact="Kidney" post="Dis.201812372384 33.NayakS.KatariaA.SharmaM.RastogiA.GuptaE.SinghA.TiwariS.HCV associated membranoproliferative glomerulonepritis treated with direct-acting antiviralsIndian"/>
  <result pre="treated with direct-acting antiviralsIndian J. Nephrol.20182846246430647501 34.ChiaX.X.CherepanoffS.DantaM.FurlongT.Successful treatment of HCV-related" exact="glomerulonephritis" post="with sofosbuvir and daclatasvirNephrology2018333738010.1111/nep.1308729520905 35.De VitaS.QuartuccioL.IsolaM.MazzaroC.ScainiP.LenziM.CampaniniM.NaclerioC.TavoniA.PietrograndeM.et al.A randomized controlled"/>
  <result pre="controlled trial of rituximab following failure of antiviral therapy for" exact="hepatitis" post="C virus associated cryoglobulinemic vasculitisArthritis Rheum.20126483584210.1002/art.3432222147444 37.RoccatelloD.SciasciaS.RossiD.SolfiettiL.FenoglioR.MenegattiE.BaldovinoS.The challenge of"/>
  <result pre="C virus associated cryoglobulinemic vasculitisArthritis Rheum.20126483584210.1002/art.3432222147444 37.RoccatelloD.SciasciaS.RossiD.SolfiettiL.FenoglioR.MenegattiE.BaldovinoS.The challenge of treating" exact="hepatitis" post="C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20"/>
  <result pre="vasculitisArthritis Rheum.20126483584210.1002/art.3432222147444 37.RoccatelloD.SciasciaS.RossiD.SolfiettiL.FenoglioR.MenegattiE.BaldovinoS.The challenge of treating hepatitis C virus-associated cryoglobulinemic" exact="vasculitis" post="in the era of anti-CD20 monoclonal antibodies and direct"/>
  <result pre="Nephrol.20164325126010.1159/00044584127161362 39.TerrierB.LaunayD.KaplanskiG.HotA.LarrocheC.CathébrasP.CombeB.De JaureguiberryJ.P.MeyerO.SchaeverbekeT.et al.Safety and efficacy of rituximab in nonviral" exact="cryoglobulinemia" post="vasculitis, data from the French Autoimmunity and Rituximab registryArthritis"/>
  <result pre="French Autoimmunity and Rituximab registryArthritis Care Res.2010621787179510.1002/acr.20318 40.FabriziF.CresseriD.FogazziG.B.MoroniG.PasseriniP.MartinP.MessaP.Rituximab therapy for" exact="primary" post="glomerulonepritis: Reports on two casesWorld J. Clin. Cases2015373674210.12998/wjcc.v3.i8.73626301235 41.FabriziF.MartinP.ElliA.MontagninoG.BanfiG.PasseriniP.CampiseM.R.TarantinoA.PonticelliC.Hepatitis"/>
  <result pre="glomerulonepritis: Reports on two casesWorld J. Clin. Cases2015373674210.12998/wjcc.v3.i8.73626301235 41.FabriziF.MartinP.ElliA.MontagninoG.BanfiG.PasseriniP.CampiseM.R.TarantinoA.PonticelliC.Hepatitis C" exact="virus infection" post="and rituximab therapy after renal transplantationInt. J. Artif. Organs20073044544910.1177/03913988070300051317551909"/>
  <result pre="Reports on two casesWorld J. Clin. Cases2015373674210.12998/wjcc.v3.i8.73626301235 41.FabriziF.MartinP.ElliA.MontagninoG.BanfiG.PasseriniP.CampiseM.R.TarantinoA.PonticelliC.Hepatitis C virus" exact="infection" post="and rituximab therapy after renal transplantationInt. J. Artif. Organs20073044544910.1177/03913988070300051317551909"/>
  <result pre="the legs after successful therapy with DAAs. pathogens-08-00176-t001_Table 1Table 1" exact="Kidney" post="disease associated with HCV: pathogenesis and clinical presentation. Kidney"/>
  <result pre="legs after successful therapy with DAAs. pathogens-08-00176-t001_Table 1Table 1 Kidney" exact="disease" post="associated with HCV: pathogenesis and clinical presentation. Kidney Disease"/>
  <result pre="1 Kidney disease associated with HCV: pathogenesis and clinical presentation." exact="Kidney" post="Disease Pathogenesis Clinical Presentation Cryoglobulinemic membranoproliferative GNs Subendothelial and"/>
  <result pre="Kidney disease associated with HCV: pathogenesis and clinical presentation. Kidney" exact="Disease" post="Pathogenesis Clinical Presentation Cryoglobulinemic membranoproliferative GNs Subendothelial and mesangial"/>
  <result pre="Subendothelial and mesangial cryoglobulin deposits;mesangial deposits of immune complexes (HCV" exact="viral" post="antigens, Ig and complement) Nephritic or nephrotic syndrome Noncryoglobulinemic"/>
  <result pre="immune complexes (HCV viral antigens, Ig and complement) Nephritic or" exact="nephrotic syndrome" post="Noncryoglobulinemic membranoproliferative GN Mesangial deposits of immune complexes (HCV"/>
  <result pre="complexes (HCV viral antigens, Ig and complement) Nephritic or nephrotic" exact="syndrome" post="Noncryoglobulinemic membranoproliferative GN Mesangial deposits of immune complexes (HCV"/>
  <result pre="syndrome Noncryoglobulinemic membranoproliferative GN Mesangial deposits of immune complexes (HCV" exact="viral" post="antigens, Ig and complement) Nephritic or nephrotic syndrome Mesangial"/>
  <result pre="immune complexes (HCV viral antigens, Ig and complement) Nephritic or" exact="nephrotic syndrome" post="Mesangial proliferative GN Direct activity of HCV on mesangium"/>
  <result pre="complexes (HCV viral antigens, Ig and complement) Nephritic or nephrotic" exact="syndrome" post="Mesangial proliferative GN Direct activity of HCV on mesangium"/>
  <result pre="(HCV viral antigens, Ig and complement) Nephritic or nephrotic syndrome" exact="Mesangial proliferative GN" post="Direct activity of HCV on mesangium Proteinuria and/or haematuria"/>
  <result pre="Direct activity of HCV on mesangium Proteinuria and/or haematuria Membranous" exact="nephropathy" post="Subepithelial deposits of immune complexes Nephrotic syndrome Berger’s disease"/>
  <result pre="and/or haematuria Membranous nephropathy Subepithelial deposits of immune complexes Nephrotic" exact="syndrome" post="Berger’s disease (IgA nephropathy) Mesangial deposits of immune complexes"/>
  <result pre="Membranous nephropathy Subepithelial deposits of immune complexes Nephrotic syndrome Berger’s" exact="disease" post="(IgA nephropathy) Mesangial deposits of immune complexes Nephritic syndrome,"/>
  <result pre="of immune complexes Nephritic syndrome, isolated proteinuria and/or haematuria Tubulo-interstitial" exact="nephritis" post="HCV deposition in tubular epithelial (perinuclear areas) and infiltrating"/>
  <result pre="isolated proteinuria and/or haematuria Tubulo-interstitial nephritis HCV deposition in tubular" exact="epithelial" post="(perinuclear areas) and infiltrating cells Proteinuria Focal and segmental"/>
  <result pre="Tubulo-interstitial nephritis HCV deposition in tubular epithelial (perinuclear areas) and" exact="infiltrating" post="cells Proteinuria Focal and segmental glomerulosclerosis Direct injury by"/>
  <result pre="epithelial (perinuclear areas) and infiltrating cells Proteinuria Focal and segmental" exact="glomerulosclerosis" post="Direct injury by HCV on podocytes of epithelial cells"/>
  <result pre="and segmental glomerulosclerosis Direct injury by HCV on podocytes of" exact="epithelial" post="cells Nephrotic syndrome, isolated proteinuria Polyarteritis nodosa Immune complexes"/>
  <result pre="HCV on podocytes of epithelial cells Nephrotic syndrome, isolated proteinuria" exact="Polyarteritis nodosa" post="Immune complexes in medium-sized muscular arteries Haematuria and/or proteinuria"/>
  <result pre="(50 mg/100 mg) Glecaprevir/Pibrentasvir (300 mg/120 mg) pathogens-08-00176-t003_Table 3Table 3" exact="Viral" post="and clinical response after antiviral therapy with DAAs in"/>
  <result pre="therapy with DAAs in patients with HCV-associated GN. DAAs SVR12" exact="Complete" post="Clinical Response Partial Clinical Response Concomitant IS Gragnani L,"/>
  <result pre="in patients with HCV-associated GN. DAAs SVR12 Complete Clinical Response" exact="Partial" post="Clinical Response Concomitant IS Gragnani L, et al. (2016)"/>
  <result pre="simeprevir, SOF, sofosbuvir. pathogens-08-00176-t004_Table 4Table 4 Treatment of HCV-related glomerular" exact="disease" post="according to clinical presentation. Presentation Treatment Non-nephrotic proteinuria DAA-based"/>
  <result pre="Non-nephrotic proteinuria DAA-based regimen (Table 1)ACEIs and/or ARBsDiuretics, anti-hypertensive agents" exact="Stable" post="and mild kidney dysfunction (GFR &amp;gt; 30 mL/min/1.72 m2)"/>
  <result pre="and mild kidney dysfunction (GFR &amp;gt; 30 mL/min/1.72 m2) Nephrotic" exact="syndrome" post="Rituximab, Plasma-exchange, IV steroids, mycophenolate mofetilDAA based regimen (Table"/>
  <result pre="(Table 1)ACEIs and/or ARBsDiuretics, anti-hypertensive agents Cryoglobulinemic flare Rapidly progressive" exact="glomerulonephritis" post="ACEIs = angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor blockers; DAAs"/>
 </snippets>
</snippetsTree>
